Syncom Formulations (India)

₹20.20As of Sun 8 Nov 2026, 12:00 UTC

NSE:SYNCOMFHealthcare

Country India

PE (Fwd) 20.31

TSR 4Y CAGR 27.48%

Div yield 0.50%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.83

PE TTM 24.84

TSR TTM 23.48%

Mkt cap ₹18.50B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹22

11.14%

(83.43%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

4.892

Revenue₹B

—

2.197

2.243

2.634

4.650

4.892

5.440

22.16%

5.20

Revenue growth%

—

2.09

17.45

76.55

5.20

11.20

11.32

—

41.39

Gross margin%

—

35.84

36.48

40.03

33.58

41.39

41.41

36.48

14.45

Operating margin%

—

7.28

6.67

9.40

10.48

14.45

14.43

9.40

15.63

Net margin%

—

9.01

8.95

9.61

10.63

15.63

15.62

9.61

24.84

P/E ratio (avg)x

—

35.78

45.05

36.18

21.20

22.34

35.98

—

26.87

EV/EBITx

—

48.03

46.07

36.71

22.93

24.20

41.39

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

0.81

EPS₹

—

0.23

0.22

0.27

0.53

0.81

0.90

37.63%

—

54.62

EPS growth%

—

(4.63)

24.58

95.28

54.62

11.19

39.60

—

Bookvalue per sh₹

—

FCF per share₹

—

0.10

Dividend per sh₹

—

0.03

—

0.10

0.12

35.12%

—

0.50

Div yield (avg)%

—

0.58

0.57

0.58

—

12.35

Payout ratio%

—

13.24

—

12.35

12.78

—

940.0

Shares (diluted)M

—

873.2

928.5

940.0

◌940.0

1.86%

—

Buyback yield%

—

(6.34)

(1.24)

—

◌—

(0.62)

—

D/E ratiox

—

18.99

Enterprise value₹B

—

7.181

11.40

17.89

16.20

18.99

31.17%

—

LT debt₹M

—

Peers (US$203.2M)

Cap (US$)

Indoco Remedies Limited

211.4M

62.81x

Venus Remedies Limited

206.5M

15.78x

Beta Drugs Limited

194.9M

40.75x

Mizuho Medy Co.,Ltd.

202.2M

9.870x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

76.61

8.745

Own earn%

—

Sh yield%

0.50

(0.62)

Owners

Insiders/Inst%

41.73

0.15

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

7–14

$1 testx

—

Incr. ROIC%

—

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹4.892B

22.16%

1.00×

Cost of revenue

₹2.867B

19.43%

0.91×

Operating expenses

₹1.318B

20.38%

0.94×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m